gpt-dict.com

Methylene Blue for Aging

Verdict: No evidence methylene blue slows aging

There is no human trial evidence that methylene blue slows aging or extends lifespan, and major regulators classify it as a prescription drug with serious interaction risks, not a longevity supplement. The current evidence base actively argues against its use for anti-aging.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

This claim earns a Counter-Evidence (D) grade because not a single human trial has tested whether methylene blue affects biological aging, age-related disease, or mortality. The strongest human study (Pang 2021, PMID 33091706) was an open-label RCT in 248 elderly surgical patients showing a single 2 mg/kg IV dose cut early postoperative cognitive dysfunction (OR 0.30). That is acute perioperative protection and cannot be stretched into a claim about chronic anti-aging supplementation.

Every 'longevity' signal rests on mechanism and animal work. A 2021 review (PMID 34943887) synthesizes redox and senescence effects but explicitly notes no human longevity trials exist, while skin-cell (Xiong 2017, PMID 28559565) and aged-mouse brain (Zheng 2020, PMID 32008150) data are preclinical only. Critically, the highest-quality controlled aging study in mice (Poudel 2024, PMID 38535998) found no in vivo benefit on skeletal aging despite favorable cell-culture results.

Authorities reinforce the negative verdict. The FDA, EU EMA, and UK MHRA all license methylene blue only as a prescription antidote for methaemoglobinaemia, with an FDA warning of serious or fatal serotonin syndrome when combined with serotonergic drugs; the WHO lists it solely as an emergency antidote. Specialty aging societies state plainly that no supplement has been shown in well-designed human trials to slow biological aging, and Harvard Health does not endorse the anti-aging use.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.51
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
85%
Highly consistent evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.15
L11 AI re-checkIndependent read
0.30
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.505
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — | C→D 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients
PMID: 33091706 2021 RCT (open-label) n = 248
Finding: Early POCD at day 7: 16.1% (MB) vs 40.2% (control), OR=0.30, p<0.001; POD: 7.3% vs 24.2%, OR=0.24, p<0.001.
Effect size: [object Object]
View on PubMed
The Potentials of Methylene Blue as an Anti-Aging Drug
PMID: 34943887 2021 系統性回顧 n = 0
Finding: MB acts as catalytic redox cycler bypassing Complex I/III; in skin cells increased cytochrome oxidase ~30%, oxygen consumption 37-70%; AD Phase 2 preliminary data reported 81% reduction in cognitive decline rate over 50 weeks; no human longevity endpoint trials exist.
Government
View on PubMed
Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging
PMID: 38535998 2024 RCT (double-blind) n = 60
Finding: Despite in vitro benefits on mitochondrial function, long-term MB and MitoQ did not prevent age-related bone loss in vivo; neither altered bone morphology or grip strength in aging mice (negative for skeletal aging endpoint).
🟢 High quality Government
View on PubMed
Anti-Aging Potentials of Methylene Blue for Human Skin Longevity
PMID: 28559565 2017 RCT (double-blind) n = 0
Finding: MB reduced mitochondrial ROS more effectively than NAC, MitoQ, or mTEM; decreased SA-β-gal and p16 in aged fibroblasts; increased dermis thickness, hydration, elastin and COL2A1; enhanced fibroblast proliferation and wound healing in 3D skin.
Academic
View on PubMed
Methylene Blue Protects Against Sevoflurane-Induced Cognitive Dysfunction in Aged Mice
PMID: 32008150 2020 RCT (double-blind) n = 45
Finding: MB attenuated sevoflurane-induced memory loss and mitochondrial fragmentation, and decreased Drp1 deSUMOylation in aged hippocampus, supporting mitochondrial protection mechanism in aging brain.
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. source↗
L4b EU EFSA
Against
Methylthioninium chloride Proveblue is used in adults and children of all ages as an antidote to treat symptoms of methaemoglobinaemia. source↗
L4c UK NHS
Against
methylthioninium chloride by the intravenous route is approved only for drug-induced methaemoglobinaemia in adults at a dose of 1–2 mg/kg source↗
L4d TW TFDA / 衛福部
Against
該藥品在國內並無許可證……醫院以專案方式進口至國內儲備，以供病患緊急所需使用。 source↗
L4e WHO
Neutral
Methylthioninium chloride (methylene blue) — Injection: 10 mg/mL in 10-mL ampoule — listed under Section 4: Antidotes and other substances used in poisonings (4.2 Specific) of the WHO Model List of Essential Medicines (23rd List, 2023). source↗
L5d Harvard Health
Against
L5e Specialty Society (condition-mapped)
Against
No supplement has been shown in well-designed human trials to slow the rate of biological aging source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-aging-INT-methylene-blue-001 繁體中文版 →